/
COCP
$1.03+$0.01 (+0.98%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$14.1M
14M shares
52-week range
$0.86 – $2.67
9% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
53.04%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-13.97
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.6M | $2.0M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $50.0K | $4.0M | $6.0M | $8.8M | $12.4M | $15.2M | $12.5M | $0 |
| Gross profit | −$50.0K | $2.6M | −$4.0M | −$8.8M | −$12.4M | −$15.2M | −$12.5M | $0 |
| Gross margin | — | 39.0% | -199.6% | — | — | — | — | — |
| R&D | $58.6M | $4.0M | $6.0M | $8.8M | $12.4M | $15.2M | $12.5M | $5.1M |
| Operating income | −$62.9M | −$48.4M | −$9.6M | −$14.2M | −$38.8M | −$18.6M | −$17.9M | −$9.0M |
| EBITDA | −$62.5M | −$2.2M | −$9.4M | −$14.0M | −$18.0M | −$21.0M | −$17.4M | −$8.5M |
| Net income | −$49.0M | −$48.2M | −$9.6M | −$14.2M | −$38.8M | −$18.0M | −$17.5M | −$8.8M |
| Net margin | — | -733.8% | -479.0% | — | — | — | — | — |
| EPS (diluted) | -21.01 | -15.78 | -2.01 | -1.85 | -4.77 | -0.00 | -1.72 | -0.78 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.69 | $-0.75–$-0.61 | 2 |
| 2027 | $0 | $-0.64 | $-0.64–$-0.64 | 1 |
| 2028 | $0 | $-0.70 | $-0.70–$-0.70 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.47
Price
$1.03
Implied downside
-54%
Peer comparison
Cocrystal Pharma, Inc. Common Stock
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
www.cocrystalpharma.com- Employees
- 10
- IPO / List date
- Apr 1, 2008
- HQ
- BOTHELL, WA
Held by traders on TradeandTell
No one on the platform currently holds COCP.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 123,928 | $125.2K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2022-10-11 | 1-for-12reverse |
| 2018-01-24 | 1-for-30reverse |
| 2011-03-15 | 10-for-1 |
Recent trades on TradeandTell
No one on the platform has traded COCP yet.
